 Vaccinex stock rocketed up more than 200 Friday, propelled by two collaboration deals centered on using the biotech companys antibody discovery platform. Vaccinex, which focuses on cancer and neurodegenerative disease, said it signed multi-project deals with two unnamed prominent pharmaceutical companies. Financial terms of the deals were undisclosed. 